The TRAVERSE Trial Explained: The Study That Rewrote TRT Safety

If you've researched testosterone replacement therapy at any point in the last decade, you've probably encountered conflicting information about whether it's safe for your heart. Some studies said TRT increased cardiovascular risk. Others said it was protective. Doctors disagreed. Patients were confused.

The TRAVERSE trial was designed to settle this debate once and for all. Published in the New England Journal of Medicine in 2023, it's the largest, most rigorous randomized controlled trial of testosterone therapy ever conducted — and its findings have fundamentally changed how both the medical community and regulators view TRT.

Here's what you need to know.

Why the TRAVERSE Trial Happened

Between 2010 and 2014, several observational studies suggested that testosterone therapy might increase the risk of heart attacks and strokes. These studies had significant methodological limitations — they weren't randomized, they often lumped different patient populations together, and some were later criticized for statistical errors — but they were enough to trigger regulatory action.

In 2015, the FDA mandated a black box warning on all testosterone products stating that TRT could increase the risk of major adverse cardiovascular events (MACE). This warning had a chilling effect: many doctors stopped prescribing testosterone, many patients stopped seeking it, and a cloud of uncertainty settled over the entire field.

The FDA also required manufacturers to conduct a large, definitive trial to resolve the question. That trial became TRAVERSE.

How the Study Was Designed

TRAVERSE was intentionally designed to be as rigorous as possible:

• Size: 5,246 men enrolled — far larger than any previous TRT trial
• Population: Men aged 45-80 with documented hypogonadism (testosterone below 300 ng/dL) and pre-existing cardiovascular disease or high cardiovascular risk factors
• Design: Randomized, double-blind, placebo-controlled — the gold standard for clinical research
• Duration: Mean follow-up of 22-33 months
• Treatment: Daily topical testosterone gel (1.62%) vs. placebo gel

The choice of study population was critical. By enrolling men who already had heart disease or were at high risk for it, the researchers were essentially stress-testing testosterone therapy in the population most likely to have problems. If TRT was going to cause cardiovascular harm, this was the group where you'd see it.

What the Trial Found

The headline result: testosterone therapy did not increase the risk of major adverse cardiovascular events.

The primary endpoint — the composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke — met the statistical threshold for non-inferiority (hazard ratio 0.96, 95% CI 0.78-1.17, p < 0.001). In plain language: TRT was statistically no worse than placebo for major heart events, even in men who already had cardiovascular disease.

The Cardiovascular Safety Question — Answered

For years, the debate over TRT and heart health was dominated by fear. The 2015 black box warning loomed large. Many doctors treated testosterone as inherently dangerous for the heart.

TRAVERSE put that fear to rest with the most definitive evidence possible. In a randomized trial specifically designed to detect cardiovascular harm, among men specifically chosen because they were at high cardiovascular risk, testosterone therapy did not increase the rate of heart attacks, strokes, or cardiovascular death.

This doesn't mean TRT is risk-free for the cardiovascular system. The trial did find a small but statistically significant increase in blood pressure, nonfatal arrhythmias, and atrial fibrillation. These are real findings that require real monitoring — which is why the FDA's updated label now includes guidance on blood pressure management rather than a blanket cardiovascular warning.

The Prostate Cancer Question — Answered

The belief that testosterone causes prostate cancer has been one of the most persistent myths in men's health. It dates back to a 1941 observation that castration (removing testosterone) could shrink existing prostate tumors. From this, the medical community extrapolated — incorrectly — that adding testosterone must cause or accelerate prostate cancer.

TRAVERSE provided definitive randomized controlled trial data: testosterone therapy did not increase the risk of prostate cancer or high-grade prostatic disease.

This aligns with what prostate cancer researchers like Dr. Abraham Morgentaler (Harvard) have argued for over a decade: testosterone at physiologic levels does not fuel prostate cancer growth. The prostate has a saturation point for androgen receptor binding, and once that's reached, additional testosterone has no effect on prostate cell proliferation.

This finding was directly cited by the December 2025 FDA panel when they recommended removing the prostate cancer warning from testosterone product labels.

The Real Risks That Were Identified

Good science doesn't just tell you what's safe — it also identifies what to watch for. TRAVERSE flagged several secondary findings that clinicians and patients should be aware of:

Blood pressure: A small but consistent increase in systolic blood pressure was observed in the testosterone group (+0.3 mmHg vs. -1.5 mmHg for placebo). For most men, this is clinically insignificant. For men with existing hypertension, it means blood pressure monitoring should be part of the TRT management plan.

Atrial fibrillation: The rate of new-onset atrial fibrillation was 3.5% in the testosterone group vs. 2.4% in placebo. While not a common side effect, men with a history of heart rhythm issues should discuss this with their provider.

Erythrocytosis (elevated red blood cells): This wasn't a primary endpoint of TRAVERSE, but it's the most common side effect of injectable TRT specifically, occurring in 11-20% of men. Elevated hematocrit increases blood viscosity and clotting risk. Regular blood work monitoring — standard at any reputable TRT clinic — catches this early.

What This Means for You

If you've been told TRT is dangerous for your heart: That advice was based on flawed observational data from 2010-2014. The best available evidence — a large, randomized controlled trial specifically designed to answer this question — shows no increased risk of major cardiovascular events. You deserve to have this conversation with your doctor using current data.

If you're on TRT and worried about long-term safety: The TRAVERSE data should be genuinely reassuring. Continue your regular monitoring schedule (blood pressure, hematocrit, PSA, metabolic panel), and know that the evidence supports the safety of properly managed TRT.

If your doctor cites cardiovascular risk as a reason to avoid TRT: Share the TRAVERSE trial data. The study was published in the New England Journal of Medicine — one of the most prestigious medical journals in the world — and it's the basis for the FDA's decision to remove the cardiovascular black box warning in February 2025.

The TRAVERSE trial isn't just a study. It's a turning point. After decades of uncertainty, we finally have definitive, high-quality evidence that testosterone therapy — when properly prescribed and monitored — is safe for the cardiovascular system. That's a foundation the entire field can build on.